Definitive Contract 75F40122C00185
Award Date
9/21/22
Potential Completion Date
9/29/24
Potential Value
$549K
Federal Agency
Food and Drug Administration
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
Silver Spring, MD 20993, USA
Solicitation Procedures
Basic Research
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $522,227.89 firm fixed-price contract awarded by the Food and Drug Administration (FDA) to the American College of Emergency Physicians (ACEP), a non-profit organization. The contract is for research on naloxone usage, safety, and efficacy in prehospital environments for conventional and emerging synthetic opioids and other combinations. This contract was awarded under a Broad Agency Announcement (BAA) solicitation from the FDA to support regulatory science and innovation. The contract...
This firm-fixed-price $200,000 purchase order was awarded by the Centers for Disease Control and Prevention (CDC) to the American College of Emergency Physicians (ACEP), a non-profit professional society for emergency physicians. The contract, which has an ultimate completion date of March 31, 2024, involves the provision of data services to the CDC. ACEP has previously received multiple federal contracts and grants from the Department of Health and Human Services to conduct research and provide...
This is a definitive cost-no-fee contract awarded by the Food and Drug Administration (FDA) to the American College of Medical Toxicology, Inc. (ACMT), a non-profit organization specializing in medical toxicology. The $1,842,760.00 contract is for a project to characterize the clinical use, risks, benefits, and effectiveness of naloxone in reversing opioid overdoses in pre-hospital settings, using qualitative and quantitative blood toxicology tests. ACMT has previously held contracts and...
This is a $675,000.00 firm-fixed price definitive contract awarded by the Centers for Disease Control and Prevention (CDC) to the American College of Emergency Physicians (ACEP) to provide supplemental hospital data for the National Hospital Care Survey. The contract has an ultimate completion date of August 31, 2027 and was awarded on September 1, 2024. There is no set-aside designation for this contract. ACEP is a leading professional society for emergency physicians that has received numerous...
This is a delivery order contract awarded by the Federal Emergency Management Agency (FEMA) to Emergent Devices, Inc., a for-profit pharmaceutical manufacturer, to purchase NARCAN nasal spray in support of FEMA's Environmental, Safety & Health Division operations. The contract has a firm fixed price of $15,921.60 and a completion date of May 31, 2024. Emergent Devices holds multiple federal contracts and grant sub-awards to supply naloxone products, including NARCAN, to various government...
This is a federal contract award to Emergent Devices, Inc., a for-profit pharmaceutical manufacturer, for the delivery of naloxone nasal spray. The contract, valued at $904,465.44, was awarded by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12. The contract is a delivery order under Emergent Devices' Federal Supply Schedule 65 IB contract for pharmaceuticals and drugs, which runs through August 2028. Naloxone is a medication used to...
This is a delivery order contract awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Emergent Devices, Inc., a for-profit manufacturer, to provide naloxone nasal spray. The contract is a firm-fixed price order under the VA's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract, with a potential value of $904,465.44. The contract does not have a set-aside designation. Naloxone is a medication that rapidly reverses opioid overdoses and is used to...
This federal contract was awarded by the Department of Veterans Affairs Veterans Health Administration to Emergent Devices, Inc., a for-profit manufacturer of pharmaceuticals and medical devices. The $1,017,630.00 contract is for the delivery of naloxone nasal spray, a medication that rapidly reverses opioid overdoses and treats substance abuse. The contract is a Delivery Order placed against Emergent Devices' Federal Supply Schedule (FSS-61-IB) contract for pharmaceuticals and drugs. No...
The Department of Veterans Affairs Veterans Health Administration awarded a $946,261.44 firm fixed price delivery order to Emergent Devices, Inc. for the provision of naloxone nasal spray. Naloxone is a medication that rapidly reverses opioid overdoses and is used to treat substance abuse. The contract is placed against Emergent Devices' Federal Supply Schedule 65 IB contract for pharmaceuticals and drugs, which runs through August 2028. The award has no set-aside designation. In addition to...
The Department of Veterans Affairs Veterans Health Administration awarded Emergent Devices, Inc., a for-profit pharmaceutical manufacturer, a firm-fixed-price delivery order contract to provide naloxone nasal spray. The $904,465.44 contract is under the Pharmaceuticals and Drugs Federal Supply Schedule 61-IB, which allows Emergent Devices to furnish drugs and hematology products to VA facilities through 2028. The naloxone nasal spray rapidly reverses opioid overdoses and treats substance...